Malaria, Malaria,Falciparum
Conditions
Keywords
Transmission, Transmission blocking vaccine, Malaria, Plasmodium falciparum, R0.6C, Vaccine
Brief summary
This is a first-in-human phase I, open-label, single-site, dose escalation study to determine the safety, tolerability and Plasmodium falciparum transmission reducing activity of the R0.6C vaccine in two different adjuvant combinations.
Detailed description
Thirty-two healthy adult volunteers will be recruited and divided over the study arms that will receive four vaccinations on days 0, 28, 56 and 168 with either 30μg or 100μg of R0.6C adjuvanted with Alhydrogel alone, or combined with Matrix-M1. Three volunteers (Group 1A, n=3) will receive four vaccinations with the lower dose of 30μg R0.6C with Alhydrogel, and, in parallel, three volunteers (Group 1B, n=3) will receive four vaccinations with the lower dose of 30μg R0.6C with Alhydrogel and Matrix-M1. Volunteers will be closely monitored for adverse events for a period of minimally 14 days after the first vaccination. If safe, an additional 5 volunteers per adjuvant arm (groups 2A and 2B) will then receive four vaccinations with the lower dose (30μg R0.6C). If considered safe following a minimum of 14 days of follow-up after the first R0.6C administration of groups 2A and 2B, three volunteers per adjuvant arm (groups 3A and 3B) will start the vaccination regimen with the higher dose of 100μg R0.6C. Finally, a minimum of 14 days after administration of the first vaccination in groups 3A and 3B, if considered safe, an additional 5 volunteers per adjuvant arm (groups 4A and 4B) will initiate the vaccination regimen with the higher dose of 100μg R0.6C. There will be no placebo group. All volunteers will be followed up for adverse events until 84 days after the last immunisation. Total trial duration is approximately 8 months for each subject. Blood will be collected to assess functional Plasmodium falciparum transmission reducing activity (TRA) and transmission blocking activity (TBA) by standard membrane feeding assay (SMFA), as well as immunogenicity, at pre-specified time points after R0.6C vaccinations compared to pre-vaccination values.
Interventions
BIOLOGICALR0.6C transmission blocking vaccine
Vaccination with R0.6C transmission blocking vaccine. Volunteers will sequentially receive four administrations of R0.6C intramuscularly in the deltoid muscle on alternating sides on days 0, 28, 56 and 168.
Sponsors
Statens Serum Institut
Novavax
Radboud University Medical Center
Study design
Allocation
RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
PREVENTION
Masking
NONE
Intervention model description
Study groups will be assigned sequentially to low and high doses of R0.6C Vaccine. Within each dose group, participants will be assigned randomly (1:1) to one of two adjuvant arms (either Alhydrogel alone or Alhydrogel + Matrix-M).
Eligibility
Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
Yes
Inclusion criteria
1. Subject must sign written informed consent to participate in the trial. 2. Subject is a male or non-pregnant and non-lactating female age ≥ 18 and ≤ 55 years and in good health. 3. Subject is able to understand planned study procedures and demonstrate comprehension of the protocol procedures and knowledge of study by passing a quiz (assessment of understanding). 4. In the opinion of the investigator, the subject can and will comply with the requirements of the protocol. 5. Subjects are available to attend all study visits and are reachable by phone throughout the entire study period from day -1 until day 224 (end of study). 6. The subject will remain within reasonable travelling distance from the study center from day -1 until day 7 after each R0.6C administration and agrees not to travel to a malaria-endemic area during the study period 7. Subject agrees to their general practitioner (GP) being informed about participation in the study and agrees to sign a form to request the release by their GP, and medical specialist when necessary, of any relevant medical information concerning possible contra-indications for participation in the study to the investigator(s). 8. The subject agrees to refrain from blood donation to Sanquin or for other purposes throughout the study period according to current Sanquin guidelines. 9. Female subjects of non-childbearing potential may be enrolled in the study. Non-childbearing potential is defined as pre-menarche, current bilateral tubal ligation or occlusion, hysterectomy, bilateral ovariectomy or post-menopause. All subjects of childbearing potential must agree to use continuous adequate contraception\* until 2 months after completion of the study. Female subjects must agree not to breastfeed from 30 days prior to R0.6C administration until 2 months after completion of the study. Female subjects must have a negative pregnancy test at the inclusion visit.
Exclusion criteria
1. Acute or chronic disease at time of R0.6C administration, clinically significant pulmonary, cardiovascular, hepatic, renal, neurological or immunological functional abnormality, as determined by medical history, physical examination or laboratory screening tests: 1. Acute disease is defined as the presence of a moderate or severe illness with or without fever. For subjects with an illness on the day of R0.6C administration, the vaccination may be postponed up to 7 days. 2. Fever is defined as an oral, axillary or tympanic temperature ≥ 38.0°C. 3. Any abnormal and clinically significant baseline laboratory screening tests of ALT, AST, creatinine, hemoglobin, platelet count or total white blood cell count, as defined in the protocol according to the FDA Toxicity Grading Scale for Healthy Adult and Adolescent Subjects Enrolled in Preventative Vaccine Clinical Trials (appendix 1). 2. History of malignancy of any organ system (other than localized basal cell carcinoma of the skin), treated or untreated, within the past 5 years. 3. Chronic use of i) immunosuppressive drugs, iii) or other immune modifying drugs within three months prior to study onset (inhaled and topical corticosteroids and oral anti-histamines exempted) or expected use of such during the study period. 4. History of drug or alcohol abuse interfering with normal social function in the period of one year prior to study onset, positive urine toxicology test for cocaine or amphetamines at screening or at inclusion. 5. Screening tests positive for Human Immunodeficiency Virus (HIV), active Hepatitis B Virus (HBV), Hepatitis C Virus (HCV). 6. Use of any other investigational or non-registered product (drug or vaccine) during the study period. 7. Known hypersensitivity to macrolides. 8. Participation in any other clinical study involving an investigational product in the 30 days prior to the start of the study or during the study period. 9. Receipt of any other vaccination within 30 days prior to the first R0.6C vaccination or planned vaccinations during the study period. Exceptions are made for vaccination against influenza and the novel coronavirus SARS-CoV2. 10. Any history of malaria, positive serology for P. falciparum, or previous participation in any malaria (vaccine) study or CHMI. 11. Body weight \> 115 kg 12. Being an employee or student of the department of Medical Microbiology of the Radboudumc at the time of screening, or a person otherwise related to the investigator. 13. Any other condition or situation that would, in the opinion of the investigator, place the subject at an unacceptable risk of injury or render the subject unable to meet the requirements of the protocol.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Serious Adverse Events and Grade 3 Adverse Events | From first immunization up to 84 days after the last immunization | The number of serious adverse events and solicited and unsolicited grade 3 adverse events possibly, probably or definitely related to the vaccine in the period from first R0.6C administration up to 84 days after the last immunization. |
| Transmission Reducing Activity | 14 days after the fourth immunization | The functional transmission reducing activity in the standard membrane feeding assay of volunteer sera collected two weeks after the fourth R0.6C immunization (I4+14), compared to baseline (I1-1) within each of the four dose-adjuvant groups. The TRA was calculated by dividing the total number of oocysts in mosquitoes fed with I4+14 sera by total number of oocysts in mosquitoes fed with I1-1 sera. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of Grade 1 and 2 Adverse Events | From first immunization up to 84 days after the last immunization | The number of solicited and unsolicited grade 1 and 2 adverse events possibly, probably or definitely related to the vaccine in the period from first R0.6C administration up to 84 days after the last immunization. |
| Transmission Reducing Activity | 14 days after immunization 1, 2 and 3. One day before immunization 4 and 84 days after immunization 4. | The transmission reducing activity at other timepoint (I1+14, I2+14, I3+14, I3+111 \[I4-1\], and I4+84) compared to baseline (I1-1) in each of the four dose-adjuvant groups. The TRA was calculated by dividing the total number of oocysts in mosquitoes fed with I1+14, I2+14, I3+14, I3+111 \[I4-1\], and I4+84 sera by total number of oocysts in mosquitoes fed with I1-1 sera. |
| Anti-6C Antibody Quantities | 14 days after each immunization. One day before immunization 4 and 84 days after immunization 4. | The anti-6C antibody quantity in volunteer sera collected two weeks after fourth R0.6C immunization (I4+14) and at other time points (I1+14, I2+14, I3+14, I3+111 \[I4-1\], and I4+84) compared to baseline (I1-1) in each of the four dose-adjuvant combinations, as determined by ELISA. |
Countries
Netherlands
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| 1A 30μg R0.6C Alhydrogel 3 subjects will receive four vaccinations of 30 ug R0.6C Alhydrogel on days 0, 28, 56 and 168.
R0.6C transmission blocking vaccine: Vaccination with R0.6C transmission blocking vaccine. Volunteers will sequentially receive four administrations of R0.6C intramuscularly in the deltoid muscle on alternating sides on days 0, 28, 56 and 168. | 3 |
| 1B 30μg R0.6C Alhydrogel + Matrix M1 3 subjects will receive four vaccinations of 30 ug R0.6C Alhydrogel + Matrix M1 on days 0, 28, 56 and 168.
R0.6C transmission blocking vaccine: Vaccination with R0.6C transmission blocking vaccine. Volunteers will sequentially receive four administrations of R0.6C intramuscularly in the deltoid muscle on alternating sides on days 0, 28, 56 and 168. | 3 |
| 2A 30μg R0.6C Alhydrogel 5 subjects will receive four vaccinations of 30 ug R0.6C Alhydrogel on days 0, 28, 56 and 168.
R0.6C transmission blocking vaccine: Vaccination with R0.6C transmission blocking vaccine. Volunteers will sequentially receive four administrations of R0.6C intramuscularly in the deltoid muscle on alternating sides on days 0, 28, 56 and 168. | 5 |
| 2B 30μg R0.6C Alhydrogel + Matrix M1 5 subjects will receive four vaccinations of 30 ug R0.6C Alhydrogel + Matrix M1 on days 0, 28, 56 and 168.
R0.6C transmission blocking vaccine: Vaccination with R0.6C transmission blocking vaccine. Volunteers will sequentially receive four administrations of R0.6C intramuscularly in the deltoid muscle on alternating sides on days 0, 28, 56 and 168. | 5 |
| 3A 100μg R0.6C Alhydrogel 3 subjects will receive four vaccinations of 100 ug R0.6C Alhydrogel on days 0, 28, 56 and 168.
R0.6C transmission blocking vaccine: Vaccination with R0.6C transmission blocking vaccine. Volunteers will sequentially receive four administrations of R0.6C intramuscularly in the deltoid muscle on alternating sides on days 0, 28, 56 and 168. | 3 |
| 3B 100μg R0.6C Alhydrogel + Matrix M1 3 subjects will receive four vaccinations of 100 ug R0.6C Alhydrogel + Matrix M1 on days 0, 28, 56 and 168.
R0.6C transmission blocking vaccine: Vaccination with R0.6C transmission blocking vaccine. Volunteers will sequentially receive four administrations of R0.6C intramuscularly in the deltoid muscle on alternating sides on days 0, 28, 56 and 168. | 3 |
| 4A 100μg R0.6C Alhydrogel 5 subjects will receive four vaccinations of 100 ug R0.6C Alhydrogel on days 0, 28, 56 and 168.
R0.6C transmission blocking vaccine: Vaccination with R0.6C transmission blocking vaccine. Volunteers will sequentially receive four administrations of R0.6C intramuscularly in the deltoid muscle on alternating sides on days 0, 28, 56 and 168. | 5 |
| 4B 100μg R0.6C Alhydrogel + Matrix M1 5 subjects will receive four vaccinations of 100 ug R0.6C Alhydrogel + Matrix M1 on days 0, 28, 56 and 168.
R0.6C transmission blocking vaccine: Vaccination with R0.6C transmission blocking vaccine. Volunteers will sequentially receive four administrations of R0.6C intramuscularly in the deltoid muscle on alternating sides on days 0, 28, 56 and 168. | 5 |
| Total | 32 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 | FG003 | FG004 | FG005 | FG006 | FG007 |
|---|---|---|---|---|---|---|---|---|---|
| Overall Study | Withdrawal by Subject | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 |
Baseline characteristics
| Characteristic | 1B 30μg R0.6C Alhydrogel + Matrix M1 | 2A 30μg R0.6C Alhydrogel | 2B 30μg R0.6C Alhydrogel + Matrix M1 | 3A 100μg R0.6C Alhydrogel | 1A 30μg R0.6C Alhydrogel | 3B 100μg R0.6C Alhydrogel + Matrix M1 | 4A 100μg R0.6C Alhydrogel | 4B 100μg R0.6C Alhydrogel + Matrix M1 | Total |
|---|---|---|---|---|---|---|---|---|---|
| Age, Categorical <=18 years | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical >=65 years | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical Between 18 and 65 years | 3 Participants | 5 Participants | 5 Participants | 3 Participants | 3 Participants | 3 Participants | 5 Participants | 5 Participants | 32 Participants |
| Age, Continuous | 50 years | 23 years | 23 years | 27 years | 22 years | 23 years | 21 years | 21 years | 23 years |
| Race/Ethnicity, Customized Asian | 0 participants | 0 participants | 1 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 1 participants |
| Race/Ethnicity, Customized Brazilian | 0 participants | 0 participants | 0 participants | 0 participants | 1 participants | 0 participants | 0 participants | 0 participants | 1 participants |
| Race/Ethnicity, Customized Caucasian | 3 participants | 5 participants | 4 participants | 3 participants | 2 participants | 3 participants | 5 participants | 5 participants | 30 participants |
| Region of Enrollment Netherlands | 3 participants | 5 participants | 5 participants | 3 participants | 3 participants | 3 participants | 5 participants | 5 participants | 32 participants |
| Sex: Female, Male Female | 2 Participants | 4 Participants | 2 Participants | 3 Participants | 1 Participants | 2 Participants | 3 Participants | 4 Participants | 21 Participants |
| Sex: Female, Male Male | 1 Participants | 1 Participants | 3 Participants | 0 Participants | 2 Participants | 1 Participants | 2 Participants | 1 Participants | 11 Participants |
| Weight (kg) | 69.2 kg | 67.0 kg | 74.0 kg | 82.6 kg | 84.6 kg | 68.0 kg | 65.4 kg | 63.8 kg | 70.1 kg |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk | EG004 affected / at risk | EG005 affected / at risk | EG006 affected / at risk | EG007 affected / at risk |
|---|---|---|---|---|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 3 | 0 / 3 | 0 / 5 | 0 / 5 | 0 / 3 | 0 / 3 | 0 / 5 | 0 / 5 |
| other Total, other adverse events | 3 / 3 | 3 / 3 | 5 / 5 | 5 / 5 | 3 / 3 | 3 / 3 | 5 / 5 | 5 / 5 |
| serious Total, serious adverse events | 0 / 3 | 0 / 3 | 0 / 5 | 0 / 5 | 0 / 3 | 0 / 3 | 0 / 5 | 0 / 5 |
Outcome results
Primary
Number of Serious Adverse Events and Grade 3 Adverse Events
The number of serious adverse events and solicited and unsolicited grade 3 adverse events possibly, probably or definitely related to the vaccine in the period from first R0.6C administration up to 84 days after the last immunization.
Time frame: From first immunization up to 84 days after the last immunization
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| 1A 30μg R0.6C Alhydrogel | Number of Serious Adverse Events and Grade 3 Adverse Events | Grade 3 adverse events | 0 adverse events |
| 1A 30μg R0.6C Alhydrogel | Number of Serious Adverse Events and Grade 3 Adverse Events | Serious adverse events | 0 adverse events |
| 1B 30μg R0.6C Alhydrogel + Matrix M1 | Number of Serious Adverse Events and Grade 3 Adverse Events | Serious adverse events | 0 adverse events |
| 1B 30μg R0.6C Alhydrogel + Matrix M1 | Number of Serious Adverse Events and Grade 3 Adverse Events | Grade 3 adverse events | 0 adverse events |
| 2A 30μg R0.6C Alhydrogel | Number of Serious Adverse Events and Grade 3 Adverse Events | Serious adverse events | 0 adverse events |
| 2A 30μg R0.6C Alhydrogel | Number of Serious Adverse Events and Grade 3 Adverse Events | Grade 3 adverse events | 0 adverse events |
| 2B 30μg R0.6C Alhydrogel + Matrix M1 | Number of Serious Adverse Events and Grade 3 Adverse Events | Grade 3 adverse events | 0 adverse events |
| 2B 30μg R0.6C Alhydrogel + Matrix M1 | Number of Serious Adverse Events and Grade 3 Adverse Events | Serious adverse events | 0 adverse events |
| 3A 100μg R0.6C Alhydrogel | Number of Serious Adverse Events and Grade 3 Adverse Events | Serious adverse events | 0 adverse events |
| 3A 100μg R0.6C Alhydrogel | Number of Serious Adverse Events and Grade 3 Adverse Events | Grade 3 adverse events | 0 adverse events |
| 3B 100μg R0.6C Alhydrogel + Matrix M1 | Number of Serious Adverse Events and Grade 3 Adverse Events | Grade 3 adverse events | 0 adverse events |
| 3B 100μg R0.6C Alhydrogel + Matrix M1 | Number of Serious Adverse Events and Grade 3 Adverse Events | Serious adverse events | 0 adverse events |
| 4A 100μg R0.6C Alhydrogel | Number of Serious Adverse Events and Grade 3 Adverse Events | Serious adverse events | 0 adverse events |
| 4A 100μg R0.6C Alhydrogel | Number of Serious Adverse Events and Grade 3 Adverse Events | Grade 3 adverse events | 0 adverse events |
| 4B 100μg R0.6C Alhydrogel + Matrix M1 | Number of Serious Adverse Events and Grade 3 Adverse Events | Grade 3 adverse events | 1 adverse events |
| 4B 100μg R0.6C Alhydrogel + Matrix M1 | Number of Serious Adverse Events and Grade 3 Adverse Events | Serious adverse events | 0 adverse events |
Primary
Transmission Reducing Activity
The functional transmission reducing activity in the standard membrane feeding assay of volunteer sera collected two weeks after the fourth R0.6C immunization (I4+14), compared to baseline (I1-1) within each of the four dose-adjuvant groups. The TRA was calculated by dividing the total number of oocysts in mosquitoes fed with I4+14 sera by total number of oocysts in mosquitoes fed with I1-1 sera.
Time frame: 14 days after the fourth immunization
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| 1A 30μg R0.6C Alhydrogel | Transmission Reducing Activity | 17 % transmission reducing activity |
| 1B 30μg R0.6C Alhydrogel + Matrix M1 | Transmission Reducing Activity | -73 % transmission reducing activity |
| 2A 30μg R0.6C Alhydrogel | Transmission Reducing Activity | -10 % transmission reducing activity |
| 2B 30μg R0.6C Alhydrogel + Matrix M1 | Transmission Reducing Activity | -3 % transmission reducing activity |
| 3A 100μg R0.6C Alhydrogel | Transmission Reducing Activity | 0 % transmission reducing activity |
| 3B 100μg R0.6C Alhydrogel + Matrix M1 | Transmission Reducing Activity | -14 % transmission reducing activity |
| 4A 100μg R0.6C Alhydrogel | Transmission Reducing Activity | 26 % transmission reducing activity |
| 4B 100μg R0.6C Alhydrogel + Matrix M1 | Transmission Reducing Activity | 13 % transmission reducing activity |
Secondary
Anti-6C Antibody Quantities
The anti-6C antibody quantity in volunteer sera collected two weeks after fourth R0.6C immunization (I4+14) and at other time points (I1+14, I2+14, I3+14, I3+111 \[I4-1\], and I4+84) compared to baseline (I1-1) in each of the four dose-adjuvant combinations, as determined by ELISA.
Time frame: 14 days after each immunization. One day before immunization 4 and 84 days after immunization 4.
Population: One subject in group 2B withdrew consent 24 days after vaccination 4, therefore the I4+84 timepoint is only analyzed in 4 out of 5 subjects of group 2B.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) |
|---|---|---|---|
| 1A 30μg R0.6C Alhydrogel | Anti-6C Antibody Quantities | I2+14 | 0.33 ug/mL |
| 1A 30μg R0.6C Alhydrogel | Anti-6C Antibody Quantities | I4+14 | 1.61 ug/mL |
| 1A 30μg R0.6C Alhydrogel | Anti-6C Antibody Quantities | I1+14 | 0.23 ug/mL |
| 1A 30μg R0.6C Alhydrogel | Anti-6C Antibody Quantities | I4+84 | 0.76 ug/mL |
| 1A 30μg R0.6C Alhydrogel | Anti-6C Antibody Quantities | I4-1 | 0.38 ug/mL |
| 1A 30μg R0.6C Alhydrogel | Anti-6C Antibody Quantities | I1-1 | 0.20 ug/mL |
| 1A 30μg R0.6C Alhydrogel | Anti-6C Antibody Quantities | I3+14 | 0.87 ug/mL |
| 1B 30μg R0.6C Alhydrogel + Matrix M1 | Anti-6C Antibody Quantities | I1+14 | 0.21 ug/mL |
| 1B 30μg R0.6C Alhydrogel + Matrix M1 | Anti-6C Antibody Quantities | I4+14 | 5.22 ug/mL |
| 1B 30μg R0.6C Alhydrogel + Matrix M1 | Anti-6C Antibody Quantities | I3+14 | 2.57 ug/mL |
| 1B 30μg R0.6C Alhydrogel + Matrix M1 | Anti-6C Antibody Quantities | I4-1 | 0.58 ug/mL |
| 1B 30μg R0.6C Alhydrogel + Matrix M1 | Anti-6C Antibody Quantities | I4+84 | 1.96 ug/mL |
| 1B 30μg R0.6C Alhydrogel + Matrix M1 | Anti-6C Antibody Quantities | I1-1 | 0.24 ug/mL |
| 1B 30μg R0.6C Alhydrogel + Matrix M1 | Anti-6C Antibody Quantities | I2+14 | 1.62 ug/mL |
| 2A 30μg R0.6C Alhydrogel | Anti-6C Antibody Quantities | I1-1 | 0.21 ug/mL |
| 2A 30μg R0.6C Alhydrogel | Anti-6C Antibody Quantities | I4-1 | 0.42 ug/mL |
| 2A 30μg R0.6C Alhydrogel | Anti-6C Antibody Quantities | I4+14 | 2.31 ug/mL |
| 2A 30μg R0.6C Alhydrogel | Anti-6C Antibody Quantities | I4+84 | 0.85 ug/mL |
| 2A 30μg R0.6C Alhydrogel | Anti-6C Antibody Quantities | I3+14 | 1.20 ug/mL |
| 2A 30μg R0.6C Alhydrogel | Anti-6C Antibody Quantities | I1+14 | 0.27 ug/mL |
| 2A 30μg R0.6C Alhydrogel | Anti-6C Antibody Quantities | I2+14 | 0.42 ug/mL |
| 2B 30μg R0.6C Alhydrogel + Matrix M1 | Anti-6C Antibody Quantities | I3+14 | 4.39 ug/mL |
| 2B 30μg R0.6C Alhydrogel + Matrix M1 | Anti-6C Antibody Quantities | I1-1 | 0.09 ug/mL |
| 2B 30μg R0.6C Alhydrogel + Matrix M1 | Anti-6C Antibody Quantities | I4+84 | 1.69 ug/mL |
| 2B 30μg R0.6C Alhydrogel + Matrix M1 | Anti-6C Antibody Quantities | I1+14 | 0.11 ug/mL |
| 2B 30μg R0.6C Alhydrogel + Matrix M1 | Anti-6C Antibody Quantities | I4+14 | 4.13 ug/mL |
| 2B 30μg R0.6C Alhydrogel + Matrix M1 | Anti-6C Antibody Quantities | I2+14 | 4.42 ug/mL |
| 2B 30μg R0.6C Alhydrogel + Matrix M1 | Anti-6C Antibody Quantities | I4-1 | 0.79 ug/mL |
| 3A 100μg R0.6C Alhydrogel | Anti-6C Antibody Quantities | I3+14 | 1.67 ug/mL |
| 3A 100μg R0.6C Alhydrogel | Anti-6C Antibody Quantities | I1-1 | 0.25 ug/mL |
| 3A 100μg R0.6C Alhydrogel | Anti-6C Antibody Quantities | I1+14 | 0.20 ug/mL |
| 3A 100μg R0.6C Alhydrogel | Anti-6C Antibody Quantities | I2+14 | 0.78 ug/mL |
| 3A 100μg R0.6C Alhydrogel | Anti-6C Antibody Quantities | I4-1 | 0.46 ug/mL |
| 3A 100μg R0.6C Alhydrogel | Anti-6C Antibody Quantities | I4+14 | 2.40 ug/mL |
| 3A 100μg R0.6C Alhydrogel | Anti-6C Antibody Quantities | I4+84 | 1.04 ug/mL |
| 3B 100μg R0.6C Alhydrogel + Matrix M1 | Anti-6C Antibody Quantities | I3+14 | 5.64 ug/mL |
| 3B 100μg R0.6C Alhydrogel + Matrix M1 | Anti-6C Antibody Quantities | I4+84 | 1.74 ug/mL |
| 3B 100μg R0.6C Alhydrogel + Matrix M1 | Anti-6C Antibody Quantities | I4-1 | 0.86 ug/mL |
| 3B 100μg R0.6C Alhydrogel + Matrix M1 | Anti-6C Antibody Quantities | I2+14 | 3.26 ug/mL |
| 3B 100μg R0.6C Alhydrogel + Matrix M1 | Anti-6C Antibody Quantities | I4+14 | 7.57 ug/mL |
| 3B 100μg R0.6C Alhydrogel + Matrix M1 | Anti-6C Antibody Quantities | I1+14 | 0.18 ug/mL |
| 3B 100μg R0.6C Alhydrogel + Matrix M1 | Anti-6C Antibody Quantities | I1-1 | 0.12 ug/mL |
| 4A 100μg R0.6C Alhydrogel | Anti-6C Antibody Quantities | I1+14 | 0.11 ug/mL |
| 4A 100μg R0.6C Alhydrogel | Anti-6C Antibody Quantities | I1-1 | 0.11 ug/mL |
| 4A 100μg R0.6C Alhydrogel | Anti-6C Antibody Quantities | I2+14 | 0.27 ug/mL |
| 4A 100μg R0.6C Alhydrogel | Anti-6C Antibody Quantities | I4-1 | 0.24 ug/mL |
| 4A 100μg R0.6C Alhydrogel | Anti-6C Antibody Quantities | I4+14 | 1.73 ug/mL |
| 4A 100μg R0.6C Alhydrogel | Anti-6C Antibody Quantities | I4+84 | 0.58 ug/mL |
| 4A 100μg R0.6C Alhydrogel | Anti-6C Antibody Quantities | I3+14 | 0.59 ug/mL |
| 4B 100μg R0.6C Alhydrogel + Matrix M1 | Anti-6C Antibody Quantities | I4+84 | 2.10 ug/mL |
| 4B 100μg R0.6C Alhydrogel + Matrix M1 | Anti-6C Antibody Quantities | I3+14 | 5.56 ug/mL |
| 4B 100μg R0.6C Alhydrogel + Matrix M1 | Anti-6C Antibody Quantities | I4+14 | 5.75 ug/mL |
| 4B 100μg R0.6C Alhydrogel + Matrix M1 | Anti-6C Antibody Quantities | I1-1 | 0.09 ug/mL |
| 4B 100μg R0.6C Alhydrogel + Matrix M1 | Anti-6C Antibody Quantities | I4-1 | 0.73 ug/mL |
| 4B 100μg R0.6C Alhydrogel + Matrix M1 | Anti-6C Antibody Quantities | I2+14 | 3.52 ug/mL |
| 4B 100μg R0.6C Alhydrogel + Matrix M1 | Anti-6C Antibody Quantities | I1+14 | 0.21 ug/mL |
Secondary
Number of Grade 1 and 2 Adverse Events
The number of solicited and unsolicited grade 1 and 2 adverse events possibly, probably or definitely related to the vaccine in the period from first R0.6C administration up to 84 days after the last immunization.
Time frame: From first immunization up to 84 days after the last immunization
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| 1A 30μg R0.6C Alhydrogel | Number of Grade 1 and 2 Adverse Events | 11 adverse events |
| 1B 30μg R0.6C Alhydrogel + Matrix M1 | Number of Grade 1 and 2 Adverse Events | 18 adverse events |
| 2A 30μg R0.6C Alhydrogel | Number of Grade 1 and 2 Adverse Events | 33 adverse events |
| 2B 30μg R0.6C Alhydrogel + Matrix M1 | Number of Grade 1 and 2 Adverse Events | 61 adverse events |
| 3A 100μg R0.6C Alhydrogel | Number of Grade 1 and 2 Adverse Events | 17 adverse events |
| 3B 100μg R0.6C Alhydrogel + Matrix M1 | Number of Grade 1 and 2 Adverse Events | 51 adverse events |
| 4A 100μg R0.6C Alhydrogel | Number of Grade 1 and 2 Adverse Events | 32 adverse events |
| 4B 100μg R0.6C Alhydrogel + Matrix M1 | Number of Grade 1 and 2 Adverse Events | 69 adverse events |
Secondary
Transmission Reducing Activity
The transmission reducing activity at other timepoint (I1+14, I2+14, I3+14, I3+111 \[I4-1\], and I4+84) compared to baseline (I1-1) in each of the four dose-adjuvant groups. The TRA was calculated by dividing the total number of oocysts in mosquitoes fed with I1+14, I2+14, I3+14, I3+111 \[I4-1\], and I4+84 sera by total number of oocysts in mosquitoes fed with I1-1 sera.
Time frame: 14 days after immunization 1, 2 and 3. One day before immunization 4 and 84 days after immunization 4.
Population: TRA data were collected first for time points with highest antibody titres, if no significant TRA was detectable at these time points, TRA data was not collected for other timepoints.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| 1A 30μg R0.6C Alhydrogel | Transmission Reducing Activity | I3+14 | 3 % transmission reducing activity |
| 1B 30μg R0.6C Alhydrogel + Matrix M1 | Transmission Reducing Activity | I3+14 | -80 % transmission reducing activity |
| 2A 30μg R0.6C Alhydrogel | Transmission Reducing Activity | I3+14 | -3 % transmission reducing activity |
| 2B 30μg R0.6C Alhydrogel + Matrix M1 | Transmission Reducing Activity | I3+14 | -9 % transmission reducing activity |
| 3A 100μg R0.6C Alhydrogel | Transmission Reducing Activity | I3+14 | 15 % transmission reducing activity |
| 3B 100μg R0.6C Alhydrogel + Matrix M1 | Transmission Reducing Activity | I3+14 | -42 % transmission reducing activity |
| 4A 100μg R0.6C Alhydrogel | Transmission Reducing Activity | I3+14 | 16 % transmission reducing activity |
| 4B 100μg R0.6C Alhydrogel + Matrix M1 | Transmission Reducing Activity | I3+14 | 9 % transmission reducing activity |